Malaria in pregnancy has devastating consequences for both mother and fetus, requiring prompt and effective treatment. The risk of infection is highest in the first trimester when many pregnancies are yet to be protected by chemoprevention with intermittent preventive treatment (IPTp) which begins in the second trimester. Up until now, artemisinin-based combination therapies (ACTs) were recommended by the WHO as first-line treatment in all patient groups, except in first-trimester women, for whom quinine with clindamycin has been recommended due to concerns about the potential embryotoxicity of artemisinins.
Although there is limited data on specific artemisinin-based combination therapies (ACTs) other than artemether-lumefantrine, the other ACTs (including artesunate-amodiaquine, artesunate-mefloquine and dihydroartemisinin-piperaquine but not artesunate–sulfadoxine–pyrimethamine) may be considered for use where artemether-lumefantrine is not available, given the demonstrated poorer outcomes of quinine treatment, along with the challenges of adherence to a seven-day course of treatment.
ACTs are already recommended for treatment in second and third trimesters. This study, the largest of its kind, was a collaborative effort between over 20 research groups with data from over 34,000 pregnancies from 12 cohort studies in ten countries collected over more than 20 years.
The meta-analysis results suggest that first-trimester treatment with artemisinin-based treatment is as safe and possibly more effective than non-artemisinin-based treatments, including quinine-based regimens. Importantly, artemether-lumefantrine, the ACT with the most safety data, was associated with 42% fewer adverse pregnancy outcomes (pregnancy loss or major congenital malformations) than oral quinine in the first trimester.
Dr Makoto Saito, Assistant Professor at The Institute of Medical Science, The University of Tokyo and part of the WorldWide Antimalarial Research Network, said: “At WWARN, we have previously shown that ACTs have a superior efficacy and much better tolerability and lower transmission risk after treatment than quinine. This new study provides an update on a previous study, confirming the evidence on safety in the first trimester using all the currently available clinical data.
“This study provides strong evidence to policy makers that ACTs should replace quinine-based regimens as the preferred treatment for uncomplicated falciparum malaria for everybody, including pregnant women in their first trimester.”
Read the publications 'Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis' on The Lancet website.